Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma
| Autor: | John H Brabson, Sharon Srebro, Pamela J. Pepsin, Gordon D. Raphael, Dennis Clifford, Kathleen Rickard, Lisa D. Edwards, Edward Kerwin |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Indoles Triamcinolone acetonide medicine.drug_class Phenylcarbamates Fluticasone propionate Pulmonary function testing Tosyl Compounds Double-Blind Method Adrenal Cortex Hormones medicine Humans Anti-Asthmatic Agents Zafirlukast Asthma Fluticasone Sulfonamides business.industry Respiratory disease General Medicine medicine.disease Respiratory Function Tests Androstadienes Treatment Outcome Anesthesia Corticosteroid Female business medicine.drug |
| Zdroj: | The American Journal of Medicine. 113:15-21 |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/s0002-9343(02)01099-9 |
| Popis: | To compare the efficacy and safety of fluticasone propionate and zafirlukast in patients with relatively stable persistent asthma who were previously treated with inhaled corticosteroids and short-acting beta(2)-agonists.A total of 440 patients (or =12 years of age) previously treated with inhaled corticosteroids (beclomethasone dipropionate or triamcinolone acetonide) and short-acting beta(2)-agonists were included in this randomized double-blind study. After an 8-day run-in period, patients were treated with fluticasone (88 microg) or zafirlukast (20 mg) twice daily for 6 weeks. Outcome measures included pulmonary function (forced expiratory volume in 1 second [FEV(1)], peak expiratory flow [peak flow]), albuterol use, asthma symptoms, withdrawals due to lack of efficacy, and asthma exacerbations. Patients treated with fluticasone (n = 224) experienced greater mean increases in FEV(1) (0.24 L vs. 0.08 L, P0.001), morning peak flow (30 L/min vs. 6 L/min, P0.001), and evening peak flow (23 L/min vs. 5 L/min, P0.001) during the study than did those treated with zafirlukast (n = 216). Fluticasone-treated patients had significantly greater increases in the mean percentages of symptom-free days (22% vs. 8%, P0.001), rescue-free days (23% vs. 10%, P = 0.002), nights with uninterrupted sleep (1% vs. -5%, P = 0.006), and fewer asthma exacerbations (1% vs. 6%, P = 0.005). Fewer fluticasone-treated patients were withdrawn due to lack of efficacy (2% vs. 13%, P0.001).Inhaled fluticasone was more effective than zafirlukast in maintaining or improving asthma control in patients with relatively stable asthma who were switched from low-dose inhaled corticosteroids. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|